1. Home
  2. VERA vs PBLS Comparison

VERA vs PBLS Comparison

Compare VERA & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$42.43

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$30.83

Market Cap

3.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VERA
PBLS
Founded
2016
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.4B
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
VERA
PBLS
Price
$42.43
$30.83
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$81.30
N/A
AVG Volume (30 Days)
2.1M
570.4K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$472.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.07
$25.56
52 Week High
$56.05
$31.51

Technical Indicators

Market Signals
Indicator
VERA
PBLS
Relative Strength Index (RSI) 59.68 63.88
Support Level $40.87 $26.68
Resistance Level $43.30 N/A
Average True Range (ATR) 2.62 2.34
MACD 0.37 0.29
Stochastic Oscillator 68.92 78.51

Price Performance

Historical Comparison
VERA
PBLS

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: